The researchers used the Langmuir monolayer technique together with atomic force microscopy to examine two lipid/cholesterol mixtures prepared at a 7:3 molar ratio: one rich in electrically neutral phosphatidylcholine groups and the other rich in negatively charged phosphatidylserine groups. They tested curcumin concentrations of 22, 41 and 253 ng/mL. Their measurements included surface pressure–mean molecular area isotherms, elastic modulus, relaxation time and microscopic film morphology.

According to the abstract, the interaction strength between curcumin and the POPS/cholesterol monolayer was significantly greater than the interaction with the POPC/cholesterol monolayer, and the two systems showed different response patterns. Atomic force microscopy results indicated that curcumin may have been adsorbed as aggregates in POPC/cholesterol monolayer films, whereas no curcumin aggregates were observed in POPS/cholesterol monolayer films. The authors proposed that the negative charge and high surface exposure of the phosphatidylserine head group could account for the stronger interaction through ion–dipole interactions.

The authors described the results as evidence for a membrane-level mechanism that may help explain curcumin’s anti-tumor selectivity and may inform delivery strategies based on differences in tumor-membrane phospholipid characteristics. Those wider implications remain interpretive: the reported experiment involved model monolayers rather than tumor or healthy cells, and the supplied abstract does not establish clinical effects, treatment outcomes or delivery performance in people. The article was also identified as an early-access version of a peer-reviewed paper that could undergo further edits.

Subject of Research: Experimental comparison of curcumin interactions with two model lipid monolayers

Article Title: Differential interactions of curcumin with POPC/cholesterol and POPS/cholesterol mixed monolayers at air-water interface

Article References: Wang, J., Wang, B., & Li, L. (2026). Differential interactions of curcumin with POPC/cholesterol and POPS/cholesterol mixed monolayers at air-water interface. Scientific Reports. https://doi.org/10.1038/s41598-026-73095-5

Image Credits: AI Generated

DOI: 10.1038/s41598-026-73095-5

Keywords: curcumin, Langmuir monolayers, POPS, POPC, cholesterol, membrane interactions, atomic force microscopy, phosphatidylserine, model membranes, Differential, interactions, mixed

The review, led by Ruyue Wang and colleagues at Shanghai Mengchao Cancer Hospital and Shanghai University, centers on the pairing of plant-derived natural products, or PDNPs, with plant-derived extracellular vesicles, known as PDEVs. These vesicles are nanoscale particles wrapped in lipid bilayers, released by plant cells through several distinct biological routes. Far from being inert packaging, they carry a dense cargo of proteins, lipids, nucleic acids, and secondary metabolites that mirror the biochemistry of their parent plant. The authors contend that PDEVs act on two fronts simultaneously: as delivery vehicles that rescue poorly behaved plant drugs, and as intrinsic anticancer agents in their own right.

Understanding how these vesicles are made is central to exploiting them. According to their biogenesis, PDEVs fall into several subtypes, including exosomes of roughly 50 to 150 nanometers, microvesicles spanning 100 to 1,000 nanometers, migrasomes that can reach 3,000 nanometers, and apoptotic bodies larger than a micrometer. The dominant production route mirrors the endosomal pathway seen in animal cells: the cell membrane folds inward to form early endosomes, which mature into multivesicular bodies that either fuse with lysosomes for degradation or release their internal vesicles into the extracellular space. Plants add two unusual twists—a vacuole-mediated route that produces ectosomes, and a plant-specific organelle called EXPO, whose double membrane resembles an autophagosome and which releases single-membrane vesicles directly into the cell wall.

Harvesting these vesicles poses a challenge unique to plants: the cell wall. Researchers must first extract the apoplastic fluid that bathes the cell exterior, then purify vesicles from that complex mixture. Milling and juicing are fast and yield high volumes but drag in cellular debris; vacuum infiltration preserves vesicle integrity but suffers from low yield; enzymatic digestion of the wall delivers high purity at the cost of added enzyme contaminants. Downstream, ultracentrifugation remains the workhorse, but newer approaches—size exclusion chromatography, tangential flow filtration, immunoaffinity capture using the tetraspanin TET8 marker, and even charge-based methods such as electrophoresis-dialysis—are reshaping the field. No single technique yet maximizes yield, purity, and functional integrity at once, and the review stresses that combination strategies will likely define the standard going forward.

Once isolated, PDEVs tackle the pharmacokinetic failures of plant drugs head-on. Hydrophobic compounds such as curcumin, resveratrol, and quercetin typically dissolve at only microgram-per-milliliter levels in water, making therapeutically relevant blood concentrations nearly impossible to achieve. The amphipathic lipid bilayer of PDEVs solves this by embedding lipophilic molecules within the membrane while passively encapsulating water-soluble cargo in the aqueous core. Ginger-derived vesicles, for instance, have demonstrated longer circulation half-lives and lower immunogenicity than synthetic nanocarriers. Loading efficiency can be striking: sonication has achieved loading capacities of up to 94 percent for curcumin in ginger-derived vesicles, far surpassing passive co-incubation or electroporation, though the physical stress can deform vesicles and blunt their native bioactivity—a trade-off the review examines candidly.

Protection from degradation is equally critical. Orally administered plant compounds are typically destroyed by gastric acid and digestive enzymes before they reach the bloodstream, while intravenously injected molecules are rapidly cleared by the liver and reticuloendothelial system. The intact phospholipid bilayer of PDEVs acts as a physical shield: ginger-derived exosome-like nanoparticles have been shown to survive simulated gastric and intestinal fluids, delivering their payload intact to the colon. Ginseng-derived nanovesicles, meanwhile, persist in circulation for more than 48 hours after injection, a half-life that dramatically outperforms free drug. Some vesicles even display inherent targeting: mulberry-derived vesicles carry the lipid MGDG, which binds the ASGPR receptor on hepatocellular carcinoma cells, steering the payload selectively toward liver tumors.

Beyond delivery, PDEVs wage their own war on cancer. Bitter melon-derived vesicles overcame chemoresistance in oral squamous cell carcinoma by triggering reactive oxygen species accumulation and mitochondrial dysfunction. Centella asiatica-derived vesicles selectively induced ROS in HepG2 liver cancer cells while sparing normal hepatocytes. Grapefruit-derived vesicles co-inhibited the PI3K/AKT and MAPK/ERK signaling axes in melanoma cells, and garlic-derived vesicles cut Bcl-2 expression by roughly 60 to 65 percent while tripling p53 levels in lung and kidney cancer lines. Lemon-derived vesicles activate the TRAIL death-receptor pathway, a mechanism validated in chronic myeloid leukemia xenografts where pro-angiogenic factors such as VEGF-A, IL-6, and IL-8 also declined. The review notes, however, that context matters: citrus-derived vesicles that kill fibrosarcoma cells leave breast cancer MCF-7 cells untouched, and some vesicles even stimulate proliferation in healthy fibroblasts—a reminder that tumor selectivity is far from universal.

PDEVs also reshape the tumor microenvironment itself. Ginseng-derived vesicles reprogram pro-tumor M2 macrophages toward an anti-tumor M1 phenotype, restore exhausted T cell function, and suppress regulatory T cells through the arginine metabolic pathway. Artemisia annua-derived vesicles activate the cGAS-STING innate immune pathway, converting tumor-associated macrophages into a pro-inflammatory state that inhibits tumor growth. When combined with immunomodulatory plant compounds, the authors argue, these effects could be potentiated into a genuinely synergistic immunotherapy platform—something no synthetic nanoparticle can replicate, because the vesicle itself is pharmacologically active.

Early clinical signals are cautiously encouraging. Only five registered clinical trials involving PDEVs exist to date, but one phase I/II study (NCT01294072) demonstrated that plant-vesicle-mediated delivery increased curcumin accumulation in colon tumor tissue relative to normal mucosa, with an acceptable safety profile. In preclinical mouse models of colon and breast cancer, vesicle-encapsulated curcumin showed markedly improved bioavailability and tumor growth inhibition compared with free drug. Orange-derived vesicles boosted curcumin bioavailability five- to six-fold, while curcumin in turn enhanced the vesicles’ own antioxidant capacity—a bidirectional interaction that hints at deeper cooperative chemistry. Paclitaxel, whose current formulations require Cremophor EL and ethanol solvents that trigger severe allergic reactions, could likewise be reformulated in vesicles to enable oral administration and eliminate excipient toxicity.

Significant obstacles remain before this vision reaches the clinic. The review identifies three core challenges: the absence of standardized isolation and characterization protocols, an incomplete mechanistic understanding of how PDNPs and PDEVs synergize at the molecular level, and a striking scarcity of long-term safety data. More than 80 percent of systemically administered plant nanovesicles accumulate in the liver and spleen, with less than 5 percent reaching intended target tissues, raising legitimate concerns about off-target hepatotoxicity and chronic immune stimulation. Batch-to-batch variability driven by plant cultivar, harvest season, and growth conditions further complicates reproducibility. The authors advocate a toxicology-first framework modeled on synthetic nanomedicine standards, alongside a Quality by Design roadmap spanning raw material standardization under GACP guidelines, scalable manufacturing through tangential flow filtration coupled with size exclusion chromatography, and a robust Chemistry, Manufacturing, and Controls package. If those pillars can be built in parallel, the review concludes, plant vesicles and plant drugs may finally fulfill their combined promise—moving from bench curiosity to bedside reality.

Subject of Research: Synergistic use of plant-derived natural products and plant-derived extracellular vesicles in cancer therapy

Article Title: Application of natural products combined with plant-derived extracellular vesicles in cancer therapy

Article References: Wang, R., Ren, M., Xu, Y., Sun, Y., & Xu, Z. (2026). Application of natural products combined with plant-derived extracellular vesicles in cancer therapy. Experimental Biology and Medicine, 251, Article 11329. https://doi.org/10.3389/ebm.2026.11329

Image Credits: AI Generated

DOI: 10.3389/ebm.2026.11329

Keywords: plant-derived extracellular vesicles, plant-derived natural products, cancer therapy, nanomedicine, drug delivery, curcumin, paclitaxel, tumor microenvironment, exosomes, biocompatibility, immunomodulation, clinical translation

The review, led by researchers from Ahmadu Bello University, Adeleke University, Babcock University, and collaborating Nigerian institutions, synthesizes preclinical, epidemiological, and emerging clinical evidence for six structurally distinct classes of plant-derived compounds: alkaloids, flavonoids, terpenoids, polyphenols, coumarins, and organosulfur compounds. These phytochemicals modulate multiple oncogenic pathways relevant to gynecological malignancies, including tumor cell proliferation, intrinsic and extrinsic apoptosis, angiogenesis, oxidative stress, inflammation, hormone receptor signaling, HPV E6/E7 oncoprotein expression, and epigenetic regulation. The authors argue that the breadth of mechanistic activity—rather than a single molecular target—distinguishes plant-derived interventions from many conventional cytotoxic agents and may explain their potential to complement standard therapies.

Paclitaxel, a taxane terpenoid isolated from the bark of Taxus brevifolia, serves as the definitive proof of concept that plant-derived compounds can achieve gold-standard clinical status in gynecological oncology. Paclitaxel stabilizes polymerized microtubules, arrests dividing cells in G2/M phase, and phosphorylates Bcl-2 to trigger apoptosis. In combination with carboplatin, it is the standard of care worldwide for advanced ovarian cancer, with a reported five-year overall survival of approximately 45 percent. Topotecan, a semi-synthetic derivative of the alkaloid camptothecin, inhibits topoisomerase I and holds regulatory approval for platinum-resistant recurrent ovarian cancer and advanced cervical cancer, based on data from Phase II/III trials including the GOG-179 study. Vincristine and vinblastine, derived from Catharanthus roseus, arrest ovarian and cervical cancer cells through beta-tubulin binding, though dose-limiting neurotoxicity restricts their use as single agents.

Among non-approved phytochemicals, the review highlights several with compelling preclinical activity. Berberine, a protoberberine alkaloid from Berberis vulgaris, inhibits proliferation and promotes apoptosis in Ishikawa endometrial carcinoma cells through modulation of PI3K/AKT signaling, with concurrent AMPK activation and NF-κB inhibition. Quercetin induces mitochondrial membrane depolarization, cytochrome c release, and caspase-3/9 activation in SKOV-3 and A2780 ovarian cancer cells while suppressing VEGF transcription in HeLa cervical cancer cells. Apigenin induces caspase-dependent apoptosis and PARP cleavage in HeLa cells and, distinctively, suppresses HPV E6/E7 oncoprotein expression—targeting the viral driver of cervical carcinogenesis rather than only downstream oncogenic effects. Kaempferol inhibits STAT3 phosphorylation and restores p53 function in cisplatin-resistant ovarian cancer cells, a mechanistically important observation given that constitutive STAT3 activation is a well-characterized driver of platinum resistance.

Polyphenols such as curcumin, resveratrol, and epigallocatechin-3-gallate (EGCG) show particular promise. Curcumin suppresses NF-κB, AP-1, and COX-2, shifts Bax/Bcl-2 ratios toward apoptosis, and downregulates HPV E6 and E7 in cervical cancer cell lines. In combination with tanshinone IIA, curcumin inhibits HPV-positive W12 cervical precancer cells at sub-IC50 doses of each agent alone. Resveratrol activates SIRT1 and inhibits PI3K/AKT/mTOR signaling, restoring taxane sensitivity in paclitaxel-resistant ovarian cancer cell lines. EGCG inhibits DNMT1, DNMT3a, and DNMT3b, reactivating silenced tumor suppressor genes through epigenetic reprogramming. The strongest clinical signal among non-approved compounds comes from EGCG in cervical precancer: a Phase II randomized trial reported 69 percent histologically confirmed regression of CIN 2/3 lesions with oral and topical EGCG at 200 mg per day, compared with 10 percent in placebo controls.

Hormone receptor modulation represents another mechanistic frontier. Soy-derived isoflavones genistein and daidzein bind estrogen receptor beta with higher affinity than estrogen receptor alpha, opposing ER-alpha-mediated proliferative signaling in the endometrium. In mice, dietary genistein and daidzein significantly reduced the incidence of endometrial adenocarcinoma and atypical hyperplasia. A meta-analysis of ten observational studies reported a 49 percent reduction in ovarian cancer risk with higher phytoestrogen intake (RR 0.51, 95% CI 0.38–0.69). The authors caution, however, that the net estrogenic or anti-estrogenic effect of phytoestrogens depends on ambient estrogen levels, receptor subtype ratios, and cancer molecular subtype, producing conflicting results across different in vitro systems that must inform patient stratification in future trials.

Coumarins and organosulfur compounds round out the mechanistic landscape. Auraptene and scopoletin exert anti-invasive and anti-proliferative effects in ovarian and endometrial cancer cells through combined inhibition of PI3K/AKT/mTOR signaling and matrix metalloproteinase activity. Importantly, coumarin derivatives demonstrate the capacity to reverse P-glycoprotein-mediated multidrug resistance—a critical contributor to platinum and taxane resistance in ovarian cancer—through direct P-gp inhibition. Allicin and related organosulfur compounds from garlic induce apoptosis in ovarian and endometrial cancer cells through ROS generation, Nrf2 pathway activation, and Bax/Bcl-2 ratio modulation, with anti-migratory effects documented through suppression of MMP-2 and MMP-9 gelatinase activity.

Poor oral bioavailability remains the most significant obstacle to clinical translation for most non-approved phytochemicals. Curcumin has oral bioavailability below 1 percent in unformulated form due to rapid intestinal and hepatic phase II metabolism, primarily glucuronidation and sulfation. EGCG undergoes catechol-O-methyltransferase-mediated methylation, substantially reducing systemic stability. Resveratrol exhibits rapid first-pass metabolism with a plasma half-life ranging from minutes to low hours. Nanoformulation strategies directly address these limitations: liposomal encapsulation improves aqueous solubility and protects compounds from presystemic metabolism, PLGA biodegradable nanoparticles provide sustained drug release, and phytosomes enhance membrane permeability. Co-administration of piperine inhibits intestinal glucuronidation and modulates efflux transporters, resulting in approximately 20-fold increases in curcumin area under the curve in human volunteer studies. Nab-paclitaxel, an albumin-bound nanoparticle formulation of paclitaxel, provides a clinically validated regulatory precedent for nanoformulated phytochemical therapeutics.

The review identifies critical barriers limiting clinical translation: botanical preparations are unstandardized, randomized trial data in gynecological cancer populations are scarce, and herb-drug interaction profiles are incompletely characterized. EGCG inhibits CYP3A4 and CYP2C9 enzymes affecting paclitaxel, cyclophosphamide, and tamoxifen metabolism; piperine broadly inhibits P-gp and other CYP isoforms, potentially increasing plasma levels of co-administered chemotherapy. High-dose isoflavone supplementation in women taking hormonal therapy for ER-positive endometrial or ovarian cancer is not currently supported by evidence. The authors call for biomarker-embedded Phase II randomized trials with pharmacokinetic sampling, molecular subtype-stratified patient selection, and rigorous evaluation of phytochemical-chemotherapy combination regimens. Precision medicine strategies—such as identifying KEAP1/NRF2-mutant ovarian tumors responsive to phytochemical-mediated oxidative stress modulators, or high-DNMT1 cervical cancers sensitive to epigenetic reprogramming—could significantly enhance the signal-to-noise ratio of future clinical trials.

Subject of Research: Health & Medicine

Article Title: Impact of plant-based interventions on gynecological cancers: a narrative review of mechanistic interplays and clinical evidence

Article References: Fabrael, F. B., Sotunsa, J., Olaniyi, K. S., Oghenetega, O. B., Adewale, O., Akindele, B. M., Olanrewaju, F., Gbimadee, N. L., Olayemi, S., Bolaji, A. O., Iyobhebhe, M. O., Adegbotoluwa, E. M., Folahanmi, E. D., Kaisar, J. A., & Oyedokun, P. A. (2026). Impact of plant-based interventions on gynecological cancers: a narrative review of mechanistic interplays and clinical evidence. Frontiers in Molecular Medicine, 6, Article 1832188. https://doi.org/10.3389/fmmed.2026.1832188

Image Credits: AI Generated

DOI: 10.3389/fmmed.2026.1832188

Keywords: gynecological cancers, phytochemicals, paclitaxel, curcumin, EGCG, HPV, nanoformulation, chemoresistance, Frontiers in Molecular Medicine, Impact, plant-based, interventions

The platform, described in the Journal of Pharmacy & Pharmaceutical Sciences, is built around quatsomes, vesicles formed from the cationic quaternary ammonium surfactant di-dodecyl-dimethyl-ammonium bromide, or DDAB, combined with cholesterol, the monoterpene limonene, and surfactants. DDAB provides the structural backbone of the bilayer while conferring a strongly positive surface charge, a property the researchers exploit deliberately. The negatively charged glomerular basement membrane and tubular epithelium attract these cationic vesicles electrostatically, encouraging drug accumulation precisely where filtration and injury converge. Cholesterol intercalates into the bilayer to stiffen it, preventing premature leakage during circulation until the carrier reaches its renal destination.

Limonene plays a quieter but equally important role. The natural monoterpene, best known as the fragrance of citrus peel, acts as an edge activator that softens the vesicle membrane, improving its deformability and its capacity to carry the lipophilic curcumin. The surfactant Span 80 adds further stability to the colloidal dispersion and improves drug solubilization. Finally, hyaluronic acid is sprinkled onto the optimized vesicles under gentle stirring, endowing the particles with an active targeting ligand. Because hyaluronic acid binds CD44 receptors, which are abundantly expressed on mesangial cells within the glomerulus, the decorated vesicles can be recognized and internalized through receptor-mediated endocytosis, adding a molecular lock-and-key dimension to the purely physical advantages of small size and positive charge.

The choice of cargo is central to the design. Curcumin, the golden polyphenol from turmeric, possesses potent antioxidant, anti-inflammatory, and antifibrotic activity, and has shown genuine nephroprotective effects in experimental models by modulating oxidative stress pathways. Yet its clinical promise has been strangled by physicochemical shortcomings: extraordinarily poor water solubility, instability at alkaline pH, rapid metabolic clearance, and consequently dismal systemic bioavailability. Encapsulation within a nanovesicular bilayer protects curcumin from degradation, solubilizes it within a hydrophobic matrix, and prolongs its presence in circulation, addressing each of these barriers simultaneously.

To build the optimal carrier, the team turned to statistical design rather than trial and error. A full 2 to the power of 3 factorial design varied three critical parameters, the DDAB-to-cholesterol ratio, the limonene-to-drug ratio, and the surfactant concentration, across two levels each, with Design-Expert software modeling how each variable influenced entrapment efficiency, particle size, polydispersity index, and zeta potential. The models proved robust, with high correlation coefficients and adequate precision values well above recommended thresholds. The winning formulation, combining a 3:1 DDAB-to-cholesterol ratio, a 6:1 limonene-to-drug ratio, and 0.8 percent surfactant, achieved a desirability score of 0.950.

The numbers behind that optimized formulation are striking. Curcumin entrapment efficiency reached 87.80 percent, meaning nearly nine of every ten drug molecules were successfully packed into the vesicles. The vesicles measured just 120.55 nanometers in diameter, comfortably below the roughly 150-nanometer threshold associated with efficient mesangial uptake, and carried a zeta potential of +38.30 millivolts, well above the ±20-millivolt mark generally required for electrostatic colloidal stability. Transmission electron microscopy confirmed uniform, spherical, discrete vesicles with no aggregation or deformation, while infrared spectroscopy verified that curcumin was physically incorporated without any chemical incompatibility among the components.

Functional testing amplified the case. In dialysis-based release studies, the formulation displayed a biphasic profile: approximately 44 percent of curcumin escaped within the first two hours as surface-associated drug diffused out, followed by sustained release governed by Higuchi diffusion kinetics from the hydrophobic bilayer interior. That initial burst could provide rapid therapeutic onset while the prolonged phase maintains drug levels and reduces dosing frequency. Most dramatically, the DPPH radical scavenging assay showed the nanoformulated curcumin lowered its IC50 from 10.99 to 2.90 micrograms per milliliter, an approximately 3.8-fold boost in antioxidant potency, reflecting enhanced solubilization, protection from degradation, and improved access to reactive oxygen species. Refrigerated storage for three months left particle size, charge, entrapment, and release behavior essentially unchanged.

The decisive test came in living animals. Rats receiving a single intraperitoneal dose of cisplatin showed the expected biochemical catastrophe, with serum creatinine rising 2.3-fold and blood urea nitrogen climbing 1.8-fold compared with healthy controls. Standard curcumin suspension offered partial relief, cutting creatinine by 37.2 percent and urea by 33.3 percent. The optimized quatsomes, delivered orally at the same 25 milligram per kilogram dose of curcumin, outperformed the free drug decisively: creatinine fell 60.5 percent and urea 40 percent relative to cisplatin-only animals, a statistically significant advantage over the plain suspension.

Histology told the same story at the cellular level. Kidneys from cisplatin-treated rats exhibited severe tubular epithelial damage, irreversible necrobiotic changes, and multiple collapsed glomeruli, earning the maximum lesion score of 3. Standard curcumin reduced the score to 2, with residual urinary space expansion and necrobiotic alterations still visible. The nanoformulated curcumin achieved a score of 1, showing only minimal, reversible cell damage and limited nuclear pyknosis in scattered renal tubules, evidence of structural preservation that tracked closely with the biochemical protection.

The authors are candid about the limits of their work. No direct biodistribution studies, such as LC-MS quantification or fluorescence imaging of kidney tissue, were performed, so renal targeting remains inferred from biomarkers and histology rather than directly measured, and CD44-mediated uptake should be treated as a plausible hypothesis rather than a confirmed mechanism. The study also lacked a drug-free nanocarrier control group. Even so, the convergence of rational design, rigorous optimization, dramatic antioxidant potentiation, and clear in vivo nephroprotection positions these hyaluronic acid-decorated quatsomes as a compelling template for the next generation of kidney-targeted nanomedicines, one that could eventually allow lower, safer doses of renoprotective agents for patients facing drug-induced kidney injury.

Subject of Research: Development of hyaluronic acid-decorated quatsomes for renal-targeted curcumin delivery and nephroprotection

Article Title: Innovative hyaluronic acid-decorated quatsomes for enhanced renal targeting: design, optimization and in-vivo biochemical and nephroprotective assessments

Article References: Ahmed, S., ElBishbishy, R. M., Sadek, M. A., & Saher, O. (2026). Innovative hyaluronic acid-decorated quatsomes for enhanced renal targeting: design, optimization and in-vivo biochemical and nephroprotective assessments. Journal of Pharmacy & Pharmaceutical Sciences, 29, Article 16787. https://doi.org/10.3389/jpps.2026.16787

Image Credits: AI Generated

DOI: 10.3389/jpps.2026.16787

Keywords: quatsomes, curcumin, renal targeting, cisplatin-induced nephrotoxicity, hyaluronic acid, DDAB, limonene, nanocarrier, CD44 receptors, mesangial uptake, antioxidant activity, nephroprotection

The engineering starts with electrospinning, a technique that draws a polymer solution through an electrified needle to produce fibers hundreds of nanometers to a few micrometers across. The researchers dissolved polycaprolactone, an FDA-approved biodegradable polyester, in hexafluoroisopropanol, ultrasonically dispersed carbon nanotubes into the mix, and spun the blend into a randomly oriented fibrous mat. Scanning electron microscopy showed a uniform, bead-free network with high porosity and surface area—an architecture deliberately designed to mimic the native extracellular matrix that skin cells naturally inhabit. Because the fibers remain at the submicron scale even after modification, the scaffold keeps the flexibility and breathability a clinical dressing would need.

Carbon nanotubes give the mat its electrical personality. The team measured conductivity on the order of 10^-2 siemens per meter, a level that falls within the range of biological tissue conductivity. Crucially, the researchers emphasize that the scaffold is not a powered device: it is designed to conduct the endogenous electrical signals that wounds naturally generate, which are known to guide cell migration, proliferation, and differentiation. After the polydopamine coating was applied, conductivity was essentially unchanged, confirming that the modification did not sever the nanotube conductive pathways. The result is a passive scaffold that speaks the wound’s own bioelectric language.

That modification is where the mussel comes in. Polydopamine, formed by the self-polymerization of dopamine under weakly alkaline conditions, mimics the adhesive proteins that let mussels cling to wet rocks. When the team dipped the PCL/CNT mats into a dopamine solution for six hours, the coating transformed the surface chemistry: the static water contact angle plummeted from 135.46 degrees to 35.30 degrees, flipping the scaffold from strongly hydrophobic to markedly hydrophilic. Energy-dispersive X-ray spectroscopy detected nitrogen on the coated fibers, chemical fingerprints of the polydopamine layer. The catechol-rich coating then served as a molecular bridge for curcumin, binding the drug through pi-pi stacking and hydrogen bonding.

The binding chemistry solved one of curcumin’s oldest problems. The compound is pharmacologically attractive—anti-inflammatory, antioxidant, and antibacterial—but notoriously insoluble and rapidly metabolized. On unmodified scaffolds, curcumin loading efficiency was a modest 27.84 percent, and more than 60 percent of the loaded drug burst out within 24 hours. With the polydopamine layer, loading efficiency jumped to 71.38 percent, and release became sustained: roughly 25 percent in the first day, about 40 percent by 72 hours, then a slow trickle thereafter. That timing matters, because the inflammatory phase of wound healing typically spans 48 to 72 hours, precisely the window in which the scaffold keeps delivering its anti-inflammatory payload. The authors candidly note the trade-off: tight binding also limits total drug release, so future versions may need higher initial loading or degradable crosslinkers to balance burst suppression against release efficiency.

In laboratory cultures, the scaffold acted like a multi-tool for repair cells. L929 fibroblasts grown with scaffold extracts proliferated faster, spread into more extended morphologies, migrated more readily, and upregulated collagen types I and III, with the collagen ratio shifting toward the more mature profile seen in quality repair. Human umbilical vein endothelial cells showed elevated CD31 expression, upregulated VEGF, and formed denser, better-connected tubular networks on Matrigel—hallmarks of activated angiogenesis. Under hydrogen peroxide-induced oxidative stress, the scaffold protected fibroblasts, endothelial cells, and macrophages alike, cutting intracellular reactive oxygen species measured by DCFH-DA fluorescence and preventing the nuclear condensation and fragmentation of apoptosis seen in unprotected cells.

The immunomodulatory results may be the most consequential. Macrophages are the conductors of the wound orchestra, and their polarization state determines whether inflammation persists or resolves. When the researchers stimulated RAW264.7 macrophages with lipopolysaccharide and interferon-gamma, scaffolds carrying curcumin and polydopamine drove the cells away from the pro-inflammatory M1 phenotype—iNOS and TNF-alpha fell—toward the reparative M2 phenotype, with Arg-1 rising sharply. That M1-to-M2 switch is the critical transition between the inflammatory and proliferative phases of healing, and the dual action of polydopamine and curcumin appears to facilitate it directly.

Against bacteria, the scaffold killed more than 90 percent of both Staphylococcus aureus and Escherichia coli in plate-counting assays. Scanning electron microscopy revealed the mechanism in grim detail: bacterial cells on the curcumin-loaded scaffold shrank, ruptured, and leaked their contents, while control bacteria stayed smooth and intact. An ONPG permeability assay confirmed that bacterial membranes became leaky, and crystal violet staining showed the scaffold significantly suppressed S. aureus biofilm formation, a key driver of chronic infection and drug resistance. More intriguingly, quantitative PCR revealed that the scaffold downregulated RecA and LexA, the regulatory genes of the bacterial SOS response—the DNA damage repair program bacteria use to survive stress. The authors propose a synergistic model: membrane disruption kills directly, while SOS suppression strips bacteria of their repair machinery. SulA, an SOS effector gene, trended upward, which the team interprets as possible compensatory feedback. Whether curcumin directly inhibits RecA function, as prior work by Bellio and colleagues suggests, or whether scaffold-induced oxidative stress indirectly perturbs the pathway remains unresolved and is flagged for future study.

The decisive test came in rats. Forty Sprague-Dawley rats each received a 10-millimeter full-thickness skin defect contaminated with infection, covered with one of the scaffold variants or left untreated. By day 7, wounds under PCL/CNT-PDA@Cur were visibly smaller than all controls; by day 14 they were almost completely closed, with closure rates significantly exceeding the other groups at every measured time point. Bacterial cultures from wound tissue confirmed infection control in vivo. Immunofluorescence of day-7 tissue showed the same immune rewiring seen in vitro: CD206-positive M2 macrophages up, CD86-positive M1 macrophages down, TNF-alpha reduced, and IL-10 elevated. Histology told the rest of the story—thicker granulation tissue, the most abundant and orderly collagen deposition by Masson’s trichrome, elevated CD31-positive vascular area at day 7, and, uniquely among the groups, hair follicle-like structures in the regenerated skin, a marker of high-quality regeneration rather than mere scar closure.

The authors are appropriately careful about limits. Rat skin heals largely through contraction of the panniculus carnosus muscle, a mechanism that differs from human re-epithelialization, so the team cautions against direct clinical extrapolation and calls for validation in large animal models such as pigs, along with quantitative assessment of re-epithelialization and collagen maturity. Still, the study assembles a coherent therapeutic cascade—immune remodeling, then angiogenesis, then tissue regeneration—within one passive dressing that requires no external power, no antibiotics, and no growth factors. If the platform survives larger animal testing, turmeric chemistry, mussel adhesion, and carbon nanotube electronics may together offer a genuinely integrated answer to the infected wounds that medicine has struggled to close.

Subject of Research: A multifunctional curcumin-loaded electroactive nanofibrous scaffold for infected wound healing

Article Title: Polydopamine-mediated curcumin-functionalized electroactive nanofibrous scaffold accelerates infected wound healing via multifactorial microenvironment remodeling

Article References: Tian, M., Bai, Y., Liu, Z., Cheng, M., Song, M., Zhou, J., Guo, W., Li, M., & Xue, J. (2026). Polydopamine-mediated curcumin-functionalized electroactive nanofibrous scaffold accelerates infected wound healing via multifactorial microenvironment remodeling. Frontiers in Bioengineering and Biotechnology, 14, Article 1959216. https://doi.org/10.3389/fbioe.2026.1959216

Image Credits: AI Generated

DOI: 10.3389/fbioe.2026.1959216

Keywords: curcumin, polydopamine, electrospinning, nanofibrous scaffold, wound healing, carbon nanotubes, bacterial SOS response, macrophage polarization, angiogenesis, oxidative stress, antibacterial biomaterials, skin regeneration

The core of the problem lies in how piperine actually works. It does not primarily help nutrients cross the intestinal wall. Instead, it inhibits the body’s machinery for eliminating foreign compounds, including the liver enzyme CYP3A4, the related enzyme CYP2C9, and the efflux transporter P-glycoprotein. These systems act as shared metabolic gatekeepers for a large fraction of orally administered drugs. When piperine blocks them, co-administered substances accumulate in the bloodstream, whether or not they are the intended target. The author, Masaki Kaneko of KYB Medical Service and KYB Orthogenics in Tokyo, compares the mechanism to the well-known food–drug interactions caused by grapefruit juice and St. John’s wort, both of which also modulate CYP3A4 activity.

The clinical consequences are not hypothetical. In controlled human pharmacokinetic studies, ten days of piperine at 20 milligrams per day increased the area under the concentration–time curve of the anticonvulsant carbamazepine by about 48 percent. In patients with epilepsy, single doses of piperine significantly raised carbamazepine concentrations and prolonged its half-life, and piperine also increased exposure to the anticonvulsant phenytoin. For the anti-inflammatory drug diclofenac, co-administration increased drug exposure by roughly 66 percent and extended its half-life by 34 percent, consistent with CYP2C9 inhibition. Physiologically based pharmacokinetic modeling predicts that 20 milligrams of piperine daily would raise exposure to several CYP3A4 substrates by more than 25 percent, including increases of about 34 percent for nifedipine, 35 percent for cyclosporine, and 59 percent for simvastatin. The greatest concern involves narrow-therapeutic-index drugs such as phenytoin and carbamazepine, where even modest increases in blood levels can trigger toxicity, including nystagmus and ataxia. Similar caution applies to anticoagulants, digoxin, and immunosuppressants.

Of the 14 tabulated drug-interaction studies, 12 showed increased exposure to the co-administered medication, spanning rifampicin, propranolol, theophylline, nevirapine, midazolam, chlorzoxazone, and fexofenadine. Two exceptions are instructive. A two-day course of a combined curcuminoid–piperine preparation did not alter the pharmacokinetics of midazolam, flurbiprofen, or paracetamol, whereas three days of piperine alone increased midazolam exposure, a discrepancy that remains unexplained. And in breast cancer patients, curcumin plus piperine reduced exposure to endoxifen, the active metabolite of tamoxifen, by 12.4 percent, showing that the direction of an interaction cannot be assumed to be an increase.

The nutrient side of the evidence tells a strikingly different story. Kaneko compiled a structured summary of 22 human pharmacokinetic studies and classified them by funding and affiliation. Nearly all the studies reporting enhanced absorption of nutrients or phytochemicals were conducted or funded by the manufacturer of the piperine ingredient, enrolled small numbers of healthy volunteers, and used plasma concentration as a surrogate endpoint. The celebrated 2,000 percent curcumin figure was calculated against a baseline so low that curcumin given alone was barely detectable in the assay. For beta-carotene, a 14-day crossover study in men with low baseline values showed a greater serum response with piperine, and for coenzyme Q10 only the 21-day, 120-milligram arm showed an increase of about 30 percent, with shorter comparisons showing no significant effect. For vitamin B6, selenium, and vitamin C, the human evidence exists, as far as the author could determine, only in manufacturer summaries or conference abstracts rather than peer-reviewed reports.

Independent trials have largely failed to confirm the enhancement claims. In three crossover studies of curcumin formulations involving 12, 30, and 9 healthy adults, piperine-containing preparations did not differ significantly from native curcumin or standard extract. Solubility-based approaches performed far better: in one trial, micellar formulations achieved 57-fold higher curcumin exposure and gamma-cyclodextrin complexes 30-fold higher, without any piperine at all. When researchers measured unconjugated curcumin separately, it remained below 2 nanomolar in most participants even after 2,280 milligrams of curcumin with 20 milligrams of piperine, suggesting that earlier studies measuring total curcumin, conjugated and unconjugated together, may have overstated the effect. For resveratrol, 20 milligrams of piperine left plasma concentrations of the parent compound and its metabolites unchanged. A 2025 three-arm study drove the point home: curcuminoid exposure rose dramatically when the proportion of long-pepper extract increased from 1 to 10 percent, yet the high-piperine arm still did not outperform a piperine-free comparator extract given at less than half the curcuminoid dose.

Beyond drug interactions, a subtler hazard arises from inadvertent supplement–supplement combinations. Curcumin appears in small amounts in many blended products marketed for joint, skin, gut, or liver support, so consumers may ingest it without considering themselves turmeric users. If they separately take a piperine-containing supplement, they unknowingly recreate the turmeric–piperine combination that has been linked to liver injury. In a United States registry series of ten adjudicated cases of turmeric-associated liver injury, five patients were hospitalized and one died; three of the seven products analyzed also contained piperine, and the investigators raised the possibility that the combination contributes to rising case numbers, though causation is unproven and absolute incidence appears low. Rising supplement-associated liver injury was highlighted at the 2026 Congress of the European Association for the Study of the Liver, and for context, supplement-related liver failure leading to liver transplant waitlisting in the United States has increased roughly eightfold over the past quarter century.

Kaneko is careful to note that piperine is not inherently a problem ingredient. Its inclusion is scientifically defensible when several conditions are met together: the target ingredient should have a documented bioavailability limitation that is mechanistically addressable by inhibiting first-pass metabolism or efflux, rather than poor solubility; enhancement should have been demonstrated in humans for the specific chemical form and dose used, preferably by independent investigators and, for heavily conjugated compounds, using the unconjugated fraction as the endpoint; the intended population should be defined and should not include people likely to be taking narrow-therapeutic-index drugs metabolized by CYP3A4, CYP2C9, or transported by P-glycoprotein; and the piperine dose should be the lowest shown to be effective, with clear label disclosure. On the evidence reviewed, few current products satisfy the second condition.

The Perspective also challenges assumptions about premium distribution channels. Labels such as “practitioner-exclusive” or “physician-dispensed” are marketing designations, not regulatory categories, and in the author’s observation piperine has now entered Japan’s clinic-dispensed supplement market, where users are especially likely to be taking prescription medications. Japan’s Foods with Function Claims framework operates on a notification system without pharmaceutical-style premarket evaluation, and the good manufacturing practice requirements that became mandatory on 1 September 2026, following the 2024 health-damage cases linked to a functional food product, address manufacturing quality rather than formulation appropriateness. A product can be manufactured to a high standard, free of contamination and accurately labeled, while still being formulated in a scientifically questionable way.

The practical implications reach clinicians, consumers, and industry alike. Clinicians should routinely ask about supplement use, including practitioner-exclusive products, when reviewing medications. Consumers can check labels for “black pepper extract,” “Piper nigrum extract,” “piperine,” or branded piperine ingredients, and should avoid unintentionally combining a piperine-containing supplement with a separate curcumin product. Label warnings advising people on anticonvulsants, anticoagulants, or immunosuppressants to consult a clinician are endorsed as necessary but insufficient, since a warning on one product cannot address risk created by combining two individually innocuous products, and cannot predict whether an interaction will raise or lower drug exposure. Regulators, the author suggests, could require that any “enhanced absorption” claim be backed by human data for the specific form and dose in the product, and pharmacovigilance systems should capture supplement–drug and supplement–supplement co-exposures. The broader message is that supplement formulation should be a deliberate, expert-driven discipline grounded in nutritional science and pharmacology, rather than an accumulation of trending ingredients, and that the ability to explain the rationale for every component is what separates a thoughtfully formulated product from one that is merely well manufactured.

Subject of Research: Piperine as a bioavailability enhancer in dietary supplements and its drug interaction risks

Article Title: Enhancement without a rationale? Black pepper extract (piperine) in dietary supplements and the future of formulation: a perspective from Japan

Article References: Kaneko, M. (2026). Enhancement without a rationale? Black pepper extract (piperine) in dietary supplements and the future of formulation: a perspective from Japan. Frontiers in Nutrition, 13, Article 1981406. https://doi.org/10.3389/fnut.2026.1981406

Image Credits: AI Generated

DOI: 10.3389/fnut.2026.1981406

Keywords: piperine, black pepper extract, dietary supplements, bioavailability, CYP3A4, P-glycoprotein, drug interactions, curcumin, turmeric, liver injury, formulation, Japan

The research team set out to test curcumin against the major molecular disturbances that characterize Huntington’s disease pathogenesis: disrupted protein homeostasis, impaired mitochondrial function, oxidative stress, altered epigenetic regulation, endoplasmic reticulum stress and inflammatory signalling. Rather than focusing on a single readout, the investigators used established HD cellular models to profile the compound’s effects across these interconnected processes, an approach that reflects the growing recognition that mutant huntingtin toxicity is not confined to one cellular compartment or pathway.

One of the central findings concerns protein aggregation, a hallmark of the disease. The mutant huntingtin protein tends to misfold and clump into aggregates that burden the cell’s quality-control machinery. In the HD cells treated with curcumin, the researchers observed a reduction in mutant huntingtin aggregation. The mechanism behind this effect appears to involve autophagy, the cellular recycling system that engulfs and degrades damaged proteins and organelles. Curcumin treatment elevated autophagic clearance, giving cells a more efficient route for disposing of the aggregation-prone protein species that accumulate in the disease state.

The study also documented a striking effect on the unfolded protein response. In HD cells, curcumin reduced PERK-eIF2α signalling, a branch of the endoplasmic reticulum stress pathway that becomes chronically activated when misfolded proteins overwhelm the folding capacity of the ER. Persistent PERK-eIF2α signalling is thought to contribute to neuronal dysfunction by throttling protein synthesis and amplifying stress responses, so its attenuation by curcumin suggests that the compound helps relieve one of the key proteostasis pressures exerted by mutant huntingtin.

Mitochondrial energetics emerged as another pathway responsive to the polyphenol. Cells carrying mutant huntingtin typically show depleted ATP levels and impaired expression of genes that govern mitochondrial biogenesis and antioxidant defense. In the curcumin-treated HD cells, ATP levels increased, and the expression of Ppargc1α and Nrf1, transcriptional regulators of mitochondrial function and oxidative stress responses, was partially restored. These shifts indicate that curcumin does not merely mop up reactive molecules downstream but may help re-establish portions of the transcriptional program that keeps mitochondria functional in vulnerable neurons.

Consistent with that mitochondrial rescue, curcumin treatment reduced both mitochondrial and cytosolic reactive oxygen species. Oxidative stress is a pervasive feature of Huntington’s disease, damaging lipids, proteins and DNA and feeding forward into further mitochondrial dysfunction. By lowering reactive oxygen species in two cellular compartments simultaneously, curcumin appears to interrupt this self-reinforcing loop, complementing its effects on ATP production and mitochondrial gene expression.

Beyond proteostasis and energetics, the study reached into epigenetic territory. The researchers found that curcumin reduced H3K27 trimethylation, a histone modification laid down by the polycomb repressive complex 2 that is dysregulated in Huntington’s disease. Huntingtin itself has been shown to facilitate PRC2 function, and aberrant histone methylation patterns are thought to contribute to the transcriptional dysregulation seen in affected neurons. The observation that a small dietary polyphenol can shift this epigenetic mark in HD cells adds a mechanistic dimension to curcumin’s profile that goes well beyond its conventional description as an antioxidant.

Perhaps the most clinically resonant result came from experiments using lymphoblastoid cell lines derived from Huntington’s disease patients. In these human cells, curcumin treatment abrogated inflammatory responses. Immune activation is now recognized as an early and progressive feature of the disease, detectable even before clinical onset, and mutant huntingtin fragmentation in immune cells has been shown to track disease progression. The finding that curcumin can suppress inflammatory signalling in patient-derived cells suggests that the compound’s anti-inflammatory reputation, documented extensively in other disease contexts, extends to the peripheral immune dimension of Huntington’s disease as well.

The authors are careful to frame curcumin as an exploratory pharmacological tool rather than a ready-made therapy, and that framing matters. Curcumin’s notoriously poor bioavailability has limited clinical translation across many candidate diseases, and the present work was conducted entirely in cellular models, which cannot capture the full complexity of a progressing neurodegenerative disorder in the living brain. Nevertheless, the breadth of the observed effects is notable. A single compound that reduces mutant huntingtin aggregation, dampens ER stress, boosts autophagic clearance, restores mitochondrial ATP and gene expression, lowers reactive oxygen species in two compartments, modulates an epigenetic mark and silences inflammatory responses in patient-derived cells provides researchers with a versatile probe for dissecting which of these pathways are causally linked in mHTT toxicity.

That probe function may prove to be the study’s most durable contribution. Huntington’s disease drug development has faced significant setbacks in recent years, including disappointing results for antisense oligonucleotide trials, and the field continues to explore complementary strategies ranging from gene therapy to stem cell approaches. Against that backdrop, a well-characterized polyphenol that touches multiple validated disease pathways in parallel offers both a research instrument and a starting point for medicinal chemistry. If future studies can identify which of curcumin’s many molecular actions are most responsible for its benefits in these models, and whether improved analogues with better drug-like properties can reproduce those effects, the humble turmeric compound may yet contribute something concrete to the long effort to slow a disease that currently has no cure.

Subject of Research: Effects of curcumin on dysregulated molecular pathways in cellular models of Huntington's disease

Article Title: Evaluation of curcumin as an exploratory pharmacological tool for modulating dysregulated molecular pathways in cellular models of Huntington’s disease

Article References: Singh, S., Mehta, R., Dabhi, R., Shah, A., Bhatt, V., Purushottam, M., Sud, R., Viswanath, B., & Vijayvargia, R. (2026). Evaluation of curcumin as an exploratory pharmacological tool for modulating dysregulated molecular pathways in cellular models of Huntington’s disease. Molecular Biology Reports, 53(1), Article 1557. https://doi.org/10.1007/s11033-026-12739-1

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12739-1

Keywords: Huntington's disease, curcumin, mutant huntingtin, autophagy, mitochondrial dysfunction, oxidative stress, endoplasmic reticulum stress, epigenetics, inflammation, neurodegeneration, polyphenol, cellular models

The review, authored by R. Mikal Lange and Tasneem P. Sharma of Indiana University School of Medicine, takes stock of why SANS has proven so stubborn. On Earth, hydrostatic pressure gradients push one to two liters of fluid toward the legs when a person stands upright, keeping intracranial pressure relatively low. In microgravity that gradient disappears, and fluid redistributes toward the head. Contrary to early expectations, lumbar puncture data and ground-based analogues suggest intracranial pressure in orbit is only mildly elevated, but it stays elevated chronically because astronauts cannot assume an upright posture. This persistent mild elevation narrows the translaminar pressure gradient across the lamina cribrosa, the meshwork where the optic nerve exits the eye, which may help drive posterior globe flattening, optic disc edema, and remodeling of the optic nerve head. Optic disc edema is detected in roughly 70 percent of crew members on long missions, appearing as early as flight day 30 and progressing throughout flight.

Mechanical forces are only part of the story. Microgravity also impairs cranial venous outflow: astronauts have shown stagnant retrograde flow in the internal jugular veins, one documented case of in-flight jugular vein thrombosis, and greater increases in dural venous sinus volumes among those who developed SANS. Emerging magnetic resonance imaging evidence points to glymphatic dysfunction as well, with perivascular spaces in white matter and basal ganglia enlarging from preflight to postflight in proportion to SANS severity. Meanwhile, galactic cosmic radiation and microgravity generate a robust oxidative stress response, producing reactive oxygen species that damage DNA, proteins, and lipids, alongside endothelial dysfunction, disrupted nitric oxide signaling, and chronic low-grade inflammation. A recent analysis even suggested that SANS may involve retinal vascular rarefaction rather than the pathological neovascularization seen in wet macular degeneration and diabetic retinopathy. Crucially, the pattern of Bruch’s membrane deformations in SANS differs from idiopathic intracranial hypertension, and one modeling study proposed that anteriorly directed force from orbital fat swelling in microgravity may press on the globe more powerfully than pressure changes alone.

Because no single unifying mechanism has been proven, Lange and Sharma hypothesize that mitigating SANS will require a multimodal approach hitting oxidative, inflammatory, microvascular, and metabolic pathways simultaneously. That is where natural compounds enter the picture. The authors argue that in space, where medical resources are limited and even mild side effects can be consequential, agents with high therapeutic indices are especially attractive. They frame these compounds primarily as prophylactic countermeasures, administered before and during flight to blunt the injury cascades that drive SANS, rather than as cures for established pathology. Their evidence base is drawn from terrestrial eye diseases, chiefly glaucoma, age-related macular degeneration, and diabetic retinopathy, which converge with SANS on the same downstream pathways of oxidative stress, endothelial dysfunction, and inflammation even though the diseases themselves are distinct.

The first candidate, Mirtogenol, combines bilberry anthocyanins with French maritime pine bark extract. Its constituents scavenge reactive oxygen species, upregulate antioxidant enzymes such as superoxide dismutase and glutathione peroxidase, boost nitric oxide production to relax blood vessels, and stabilize leaky retinal capillaries. In a prospective controlled trial of 38 people with elevated intraocular pressure, Mirtogenol lowered pressure from about 25.2 to 22.0 millimeters of mercury over two to three months while improving blood flow in the central retinal, ophthalmic, and posterior ciliary arteries, and a Wistar rat glaucoma model showed reduced retinal ganglion cell apoptosis. The authors stress that the rationale in space is not pressure lowering, since in-flight intraocular pressure rises only about 1.3 millimeters of mercury on average, but rather antioxidant, anti-inflammatory, and vasoprotective effects that could counter venous congestion. Safety data across six months showed no observed adverse effects.

Ginkgo biloba extract, particularly the standardized EGb 761 formulation, offers a complementary profile. Its flavonoids scavenge reactive oxygen and nitrogen species, its terpenoids upregulate reducing enzymes including catalase and heme-oxygenase 1, and the extract improves blood rheology by promoting erythrocyte deformability, raising nitric oxide, and lowering fibrinogen, thereby inhibiting microthrombus formation. Studies in normal-tension glaucoma have yielded mixed results on visual field preservation, with one four-year observational study reporting significant improvement while a four-week randomized crossover trial in 28 patients found no benefit. However, human studies consistently show increased ophthalmic artery and retrobulbar blood flow velocities, and rodent work demonstrates increased choroidal blood flow. Systematic reviews found no significant difference in adverse events versus placebo across 80 to 600 milligrams daily, though one review flagged a possible association with bleeding risk that a 50-volunteer coagulation study failed to confirm.

Saffron and its constituents crocin and crocetin bring a different mechanism: activation of the NRF2 transcription factor, which switches on endogenous antioxidant genes, plus suppression of the pro-inflammatory NF-κB pathway and demonstrated enhancement of oxygen diffusion and ocular blood flow in animal studies. In clinical trials, saffron preserved visual acuity and retinal flicker sensitivity in age-related macular degeneration, lowered intraocular pressure as an adjunct to timolol and dorzolamide in a pilot glaucoma study, and improved central macular thickness, visual acuity, and HbA1c in diabetic maculopathy at 15 milligrams daily. Doses under 1.5 grams per day show no excess adverse events, and therapeutic ocular doses run 15 to 50 milligrams daily, giving the spice a high therapeutic index. Curcumin, the turmeric-derived polyphenol, scavenges free radicals, blocks NF-κB, induces heme oxygenase-1, and restored mitochondrial function in a rodent ischemia-reperfusion glaucoma model. Yet the authors caution a critical caveat: curcumin and resveratrol are both anti-angiogenic, and since SANS may involve retinal vascular rarefaction, dampening new vessel growth could theoretically backfire.

The remaining candidates round out four overlapping mechanistic domains. Coenzyme Q10 sits at the heart of the mitochondrial electron transport chain and acts as a potent antioxidant; in a 106-patient trial, a regimen including 30 milligrams daily improved visual field mean defect and foveal sensitivity in macular degeneration, and glaucomatous mice given CoQ10 showed greater retinal ganglion cell survival. Resveratrol upregulates NRF2 and HO-1 antioxidant pathways and suppresses NF-κB, reducing TNF-α, IL-1β, and IL-6, with observational data in wet macular degeneration showing fewer anti-VEGF injections over 24 months. Vitamin E isoforms have demonstrated radioprotective properties, shielding mouse bone marrow and human CD34+ cells from radiation damage, which is directly relevant to cosmic ray exposure, though the NIH tolerable upper limit of 1,000 milligrams daily must be respected to avoid bleeding complications. B vitamins occupy a uniquely SANS-specific niche: astronauts with detectable SANS showed 25 to 45 percent higher serum homocysteine, cystathionine, and methylmalonic acid, and polymorphisms in the one-carbon metabolism genes MTRR and SHMT1 have been linked to chorioretinal folds and optic disc edema, with B-vitamin status predicting ocular outcomes.

The authors are careful to underline how preliminary all of this remains. No spaceflight or analogue studies of these compounds have been conducted, and a single documented in-flight case, in which an astronaut with two genetic risk factors received B6, methylfolate, B12, and riboflavin from flight day 153, showed improvement but was confounded by natural disease course and a simultaneous reduction in cabin carbon dioxide. Practical hurdles also loom: pharmaceuticals degrade faster in space due to radiation, humidity swings, and vibration, so any countermeasure must survive a multi-year Mars mission without resupply, and altered pharmacokinetics in microgravity could change how supplements are absorbed and cleared. To move forward, the review proposes two testable hypotheses: that pre- and in-flight supplementation with an antioxidant or vasoregulatory compound reduces optic disc edema and choroidal thickening, and that combining metabolic supplementation with mechanical countermeasures such as lower body negative pressure yields additive protection. Head-down tilt bed rest, supine bed rest, and rodent unloading models that reproduce retinal nerve fiber changes now offer tractable platforms to put kitchen-sack pharmacology to the test before the first crew leaves for the Red Planet.

Subject of Research: Natural compounds as potential countermeasures for spaceflight-associated neuro-ocular syndrome

Article Title: Natural compounds as potential countermeasures for spaceflight-associated neuro-ocular syndrome

Article References: Lange, R. M., & Sharma, T. P. (2026). Natural compounds as potential countermeasures for spaceflight-associated neuro-ocular syndrome. Frontiers in Ophthalmology, 6, Article 1801651. https://doi.org/10.3389/fopht.2026.1801651

Image Credits: AI Generated

DOI: 10.3389/fopht.2026.1801651

Keywords: spaceflight-associated neuro-ocular syndrome, SANS, microgravity, oxidative stress, astronaut vision, natural compounds, Mirtogenol, Ginkgo biloba, saffron, curcumin, coenzyme Q10, B vitamins

The stakes of the research are considerable. According to data cited by the authors, roughly 890 million people worldwide live with obesity and 589 million adults aged 20 to 79 live with diabetes, while nearly 197 million more suffer from impaired glucose tolerance. Modern Western dietary patterns, dominated by calorie-dense, high-fat and processed foods, drive much of this crisis. Crucially, scientists now view obesity not merely as an over-accumulation of fat but as a state of chronic, low-grade tissue inflammation. That inflammation fuels insulin resistance, which in turn progresses toward type 2 diabetes, and it disrupts the regulation of metabolic hormones such as leptin and adiponectin that normally keep appetite and energy balance in check.

To model this pathology, the team turned to the workhorse of metabolic research: the high-fat diet mouse. Forty Swiss albino mice, each weighing about 23 grams and aged six to eight weeks, were randomly assigned to five groups of eight animals. One group received a normal diet, one received a high-fat diet deriving 60 percent of its calories from fat, and three treatment groups ate the high-fat diet while receiving curcumin at 90 milligrams per kilogram of body weight, disulfiram at 200 milligrams per kilogram, or both compounds together by oral gavage over 12 weeks. The researchers then tracked food intake, body weight, the Lee obesity index, fasting glucose, glycated hemoglobin, glucose tolerance, serum insulin and leptin, lipid profiles, liver enzymes, and liver histology.

The results on food intake and body weight were dramatic. From the fifth week onward, high-fat diet mice treated with either compound ate significantly less food; by week 12, curcumin-treated mice had consumed 16.76 grams and disulfiram-treated mice 17.68 grams, compared with 23.54 grams in the untreated high-fat group. The combination group ate even less, roughly 32 percent below the high-fat-only animals and lower than even the normal chow controls. Body weight followed the same pattern. The untreated high-fat mice ballooned to a mean of 36.70 grams, nearly 40 percent heavier than controls, while the curcumin group reached only 28.28 grams, a 22.94 percent reduction in weight gain, the largest numerical drop of any intervention. The combination stabilized around 29.32 grams and disulfiram alone at 29.40 grams.

Metabolic measurements reinforced the picture. The Lee obesity index, a standard morphometric gauge of adiposity, climbed above 310 in the untreated high-fat mice but stayed below that threshold in all three treated groups. Fasting blood glucose in the high-fat group reached 230 milligrams per deciliter, more than double the control value of 112.67, and glycated hemoglobin rose more than two-fold to 6.55 millimoles per mole, confirming long-term hyperglycemia and type 2 diabetes. Here the synergy became unmistakable: curcumin and disulfiram monotherapies each lowered HbA1c, but the combination brought it down to 4.68 millimoles per mole, the value closest to the control baseline of 3.10.

Glucose tolerance testing told a similar story. Untreated high-fat mice began the oral glucose tolerance test at nearly double the control baseline glucose and remained highly elevated even after 120 minutes, with an area under the curve almost 54 percent larger than controls. Both monotherapies restored 120-minute glucose to around 108 milligrams per deciliter, but the combination group cleared the glucose load fastest, peaking at just 165 milligrams per deciliter at 15 minutes and falling to 123 by the two-hour mark while maintaining the most stable overall profile. The hormonal data were equally striking. Untreated high-fat mice showed roughly five-fold elevated insulin and a six-fold increase in the HOMA-IR index of insulin resistance, along with leptin levels of 13.28 nanograms per milliliter versus 4.27 in controls, hallmarks of compensatory insulin hypersecretion and leptin resistance. The combination treatment restored insulin almost entirely to the control baseline of 0.76 nanograms per milliliter and cut leptin to 6.01, outperforming either drug alone.

The liver, a central casualty of diet-induced obesity, also benefited. Untreated high-fat mice developed severely deranged lipid profiles, with triglycerides of 120.54 milligrams per deciliter and cholesterol of 208.23 versus control values of 96.20 and 92.20 respectively, alongside sharply elevated LDL and depressed HDL. The combination treatment brought all four lipid parameters back to levels statistically indistinguishable from controls. Liver injury enzymes told the same tale: serum SGPT rose from 42.96 to 87.28 units per liter and SGOT from 70.18 to 152.40 in the high-fat group, but the combination drove SGPT down to 43.99, essentially the control value, and SGOT to 105.93, better than either monotherapy. Under the microscope, the untreated high-fat livers showed inflammatory cell infiltration, ballooning hepatocytes, and extensive intracellular fat droplets, while the combination-treated livers regained an architecture closely resembling healthy tissue, with only mild sinusoidal dilations persisting.

Mechanistically, the two compounds attack obesity from complementary angles. Disulfiram, historically known as Antabuse, inhibits aldehyde dehydrogenase, and because the ALDH1A1 enzyme participates in retinoic acid biosynthesis and energy homeostasis, blocking it promotes weight loss. The drug has also been shown to suppress the NLRP3 inflammasome, a key driver of chronic inflammation and insulin resistance, and to activate autophagy, improving glucose handling. Curcumin, meanwhile, deploys phenolic hydroxyl groups with potent antioxidant activity that protect the liver and pancreas, and it activates AMP-activated protein kinase, a cellular fuel gauge that promotes glucose uptake in muscle, stimulates fatty acid oxidation, and inhibits gluconeogenesis in the liver. Together, reduced appetite, dampened inflammation, and improved glucose and fat metabolism appear to reinforce one another.

The authors are careful to note that enthusiasm must be tempered by caveats. The 200 milligrams per kilogram disulfiram dose used in mice converts, by standard body surface area methods, to roughly 1,000 milligrams per day in humans, well above the FDA-approved maximum of 500 milligrams per day, and disulfiram has been associated with neurological and psychological adverse events. Curcumin, for its part, suffers from poor bioavailability, limiting how much active compound actually reaches tissues. The team calls for comprehensive toxicological assessment of disulfiram and for advanced delivery methods, such as the nanoparticle formulations already showing promise in vitro, to improve curcumin’s clinical utility. The study was approved by the Institutional Animal Ethical Committee at Banaras Hindu University.

Still, as a proof of concept, the findings are compelling. Mice eating an obesity-inducing diet stayed lean, kept their glucose tolerance, normalized their hormones and blood fats, and protected their livers, all with two inexpensive and widely available compounds, one of them sitting in the spice rack. If future work can resolve the safety and bioavailability questions, the curcumin-disulfiram pairing could offer a cost-effective preventive strategy against the intertwined epidemics of obesity and type 2 diabetes, a goal that conventional single-drug approaches have struggled to achieve.

Subject of Research: Synergistic anti-obesity effects of curcumin and disulfiram in high-fat diet-fed mice

Article Title: Anti-obesogenic potential of curcumin, disulfiram, and their synergistic effects in HFD-fed obese Swiss albino mice

Article References: Patel, J. K., More, R. S., Singh, A. N., & Gupta, A. (2026). Anti-obesogenic potential of curcumin, disulfiram, and their synergistic effects in HFD-fed obese Swiss albino mice. Frontiers in Endocrinology, 17, Article 1954754. https://doi.org/10.3389/fendo.2026.1954754

Image Credits: AI Generated

DOI: 10.3389/fendo.2026.1954754

Keywords: curcumin, disulfiram, obesity, type 2 diabetes, high-fat diet, insulin resistance, leptin, fatty liver, drug repurposing, mouse model, metabolic syndrome, HOMA-IR

The commercial stakes are enormous. The global nanomedicine market was valued at 263.68 billion US dollars in 2025 and is projected to reach 759.09 billion dollars by 2034, growing at a compound annual rate of 12.83 percent, with North America holding a 46.12 percent share. Natural product-derived drugs continue to account for a significant proportion of newly approved small-molecule therapeutics, making the marriage between nanotechnology and natural chemistry one of the most consequential trends in modern drug development. By precisely tuning particle size, surface charge, and microenvironmental responsiveness, nanocarriers can cross biological barriers, boost the solubility of poorly soluble drugs, prolong retention at lesion sites, and enhance bioavailability while reducing toxicity.

Hydrogel nanocarriers represent one of the most versatile platforms described in the review. These three-dimensional crosslinked networks, held together by hydrogen bonding, pi-pi stacking, and hydrophobic effects, can transform hydrophobic herbal molecules into injectable depots. In pancreatic cancer models, a carrier-free hydrogel co-assembled from puerarin and deacetylasperulosidic acid reduced tumor cell viability to 21.39 percent, while an adenosine-gentisic acid hydrogel that targets mitochondria pushed the apoptosis rate of SW1990 cells to 33.5 percent. Smart hydrogels are also being designed to dismantle multidrug resistance by softening stiff tumor matrix, relieving hypoxia, and reactivating antitumor immunity, potentially converting drug-resistant cold tumors into therapy-sensitive hot ones.

Clinical translation of hydrogels, however, has proven difficult. OncoGel, a thermosensitive PLGA-PEG-PLGA hydrogel encapsulating paclitaxel, was tested in a phase IIb trial of 154 patients with advanced esophageal cancer. Interim safety analysis showed the intratumoral injection was well tolerated, with mostly mild local adverse reactions and no increase in systemic toxicity, yet no efficacy endpoints were ever disclosed and the product never advanced to phase III. The case illustrates a sobering gap between the safety advantages of hydrogel carriers and the demonstration of definitive benefit, compounded by low drug loading, weak intrinsic targeting, protein corona formation after systemic administration, and severe batch-to-batch variability from natural sources.

Lipid-based nanocarriers, by contrast, are the most clinically mature platform. Liposomes, solid lipid nanoparticles, and nanostructured lipid carriers exploit biomembrane-mimetic bilayers to encapsulate both hydrophilic and hydrophobic natural drugs. Preclinical successes are striking: pH-sensitive liposomes coloaded with dihydroartemisinin and tetrandrine reversed doxorubicin resistance in breast cancer by up to 46.70 percent while reducing cardiotoxicity, aptamer-modified liposomes carrying norcantharidin and paeonol achieved a 77.67 percent hepatic tumor inhibition rate, and ApoE-functionalized liposomes delivered artesunate derivatives deep into drug-resistant glioblastoma. Approved products validate the pathway: Marqibo for relapsed acute lymphoblastic leukemia, Onivyde for metastatic pancreatic cancer based on the NAPOLI-1 trial showing median overall survival of 6.1 versus 4.2 months, and the Chinese paclitaxel liposome Lipusu, which in real-world studies of advanced lung cancer combined with immunotherapy produced a median overall survival of 30.5 months.

Even liposomal curcumin has reached patients. In a phase I dose-escalation study of 32 patients with advanced solid tumors, Lipocurc established safety and tolerability, with curcumin plasma concentrations reaching 1,428 to 1,641 nanograms per milliliter at the 300 milligrams per square meter dose. Although no objective tumor responses were observed, one prostate cancer patient’s PSA fell from 649 to 355 nanograms per milliliter and a colon cancer patient’s CEA dropped from 18,542 to 6,441 micrograms per liter, providing rare clinical evidence that nanodelivery can overcome the notoriously low bioavailability of plant polyphenols. Challenges remain, including the accelerated blood clearance phenomenon after repeated PEGylated injections and limited loading capacity for poorly water-soluble drugs.

Polymeric nanocarriers form the second pillar of translation. Genexol-PM, a Cremophor-free micellar paclitaxel formulation approved in Korea, achieved a 58.5 percent overall response rate in metastatic breast cancer without routine premedication, while the micelle NK105 met safety goals in a phase III trial of 436 patients, cutting severe peripheral neuropathy from 7.5 percent to 1.4 percent compared with conventional paclitaxel, though it narrowly missed its noninferiority endpoint for progression-free survival. The camptothecin nanoparticle CRLX101 provided direct proof of tumor localization in a biopsy study, with fluorescence detectable in all post-treatment tumor samples and none in adjacent healthy tissue. Biomimetic systems add another layer of sophistication: Abraxane, the albumin-bound paclitaxel approved for breast, lung, and pancreatic cancer, exploits the endogenous gp60-SPARC transport pathway and demonstrated a 33 percent versus 19 percent response rate advantage over solvent-based paclitaxel in its pivotal trial, with far less severe neutropenia.

The review also catalogs emerging platforms with high potential but low maturity. Natural polysaccharide-derived carriers built from Astragalus, Dendrobium, and Ganoderma polysaccharides combine drug delivery with intrinsic immunomodulation, yet raw material heterogeneity makes GMP standards nearly impossible to establish. Mesoporous silica and metal-organic frameworks offer enormous surface area and drug-loading capacity, with curcumin-loaded IRMOF-16 and oridonin-loaded MOF-5 showing potent antitumor activity, but framework hydrolysis, burst release, and poorly characterized long-term toxicity keep them preclinical. Biomimetic carriers using erythrocyte membranes, exosomes, yeast cell walls, transferrin, and ferritin achieve immune evasion and homotypic targeting, but scale-up of ultrasonication and extrusion processes remains a fundamental bottleneck.

The authors argue the field is undergoing a paradigm shift from one-size-fits-all nanocarriers toward precision nanomedicines. Future priorities include multi-stimuli-responsive carriers that release payloads sequentially in response to pH, reactive oxygen species, enzymes, and temperature; integration with immunotherapy such as checkpoint blockade and CAR-T cells; genetically engineered protein cages; and artificial intelligence-driven prediction of carrier-drug interactions to screen optimal materials and process parameters. They also highlight an underappreciated frontier: nanocarriers that counteract therapy-induced toxicity, such as systems designed to neutralize the Thbs1-enriched extracellular vesicles that irradiated tumors release to damage the heart.

For now, the hierarchy of translational readiness is clear: lipid carriers lead, followed by polymeric systems and albumin technology, while hydrogels, inorganic frameworks, and polysaccharide carriers remain largely preclinical. Yet the trajectory is unmistakable. As interdisciplinary integration of materials science, biochemistry, and computational design accelerates, the therapeutic potential locked inside curcumin, berberine, paclitaxel, artemisinin, and hundreds of other natural molecules is finally being unlocked, one nanoscale vehicle at a time, promising a future where nature’s most powerful chemistry can reach the right target at the right dose with minimal harm.

Subject of Research: Nanocarrier-based delivery systems for natural drug molecules and their clinical translation

Article Title: Advanced nanocarrier delivery and therapeutic systems for natural drug molecules: mechanisms, applications, and future perspectives

Article References: Zhang, Y., Li, T., Chen, Y., & Ge, J. (2026). Advanced nanocarrier delivery and therapeutic systems for natural drug molecules: mechanisms, applications, and future perspectives. Journal of Advanced Research. https://doi.org/10.1016/j.jare.2026.10.024

Image Credits: AI Generated

DOI: 10.1016/j.jare.2026.10.024

Keywords: nanocarriers, natural products, drug delivery, liposomes, hydrogels, polymeric nanoparticles, biomimetic nanocarriers, paclitaxel, curcumin, nanomedicine, clinical translation, targeted therapy